Analysts Offer Insights on Healthcare Companies: Tesaro (TROV) and TrovaGene (TROV)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tesaro (NASDAQ: TSRO) and TrovaGene (NASDAQ: TROV) with bullish sentiments.

Tesaro (NASDAQ: TSRO)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Tesaro (NASDAQ: TSRO) today and set a price target of $122. The company’s shares closed on Friday at $46.89, close to its 52-week low of $42.81.

Cann observed:

“We believe this analysis of TOPACIO continues to support our outlook for the use of Zejula in ovarian cancer. The ASCO presentation was to a very large audience, which we believe will greatly increase awareness of these data. As a result, we are maintaining our current sales estimates for Zejula. Investigators stated that Zejula in combination with a PD-1 inhibitor provides clinical benefit in patients with platinum- resistant and platinum-refractory disease.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 20.0% and a 62.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Currently, the analyst consensus on Tesaro is Moderate Buy and the average price target is $85.43, representing an 82.2% upside.

In a report issued on May 31, Citigroup also reiterated a Buy rating on the stock with a $100 price target.

See today’s analyst top recommended stocks >>

TrovaGene (NASDAQ: TROV)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on TrovaGene (NASDAQ: TROV), with a price target of $7. The company’s shares closed on Friday at $0.22, close to its 52-week low of $0.21.

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.4% and a 42.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

TrovaGene has an analyst consensus of Moderate Buy, with a price target consensus of $7.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts